University of Ioannina
Συσχέτιση της ηπατικής ίνωσης εκτιμώμενης με ελαστογραφία με τις διαταραχές της πηκτικότητας σε ασθενείς με κίρρωση του ήπατος
Abstract
dc:descriptionTitle: Correlation of hepatic fibrosis assessed by elastography with coagulation disorders in patients with liver cirrhosis. Background: Liver fibrosis occurs due to persistent liver damage from various causes and is characterized by overproduction of extracellular matrix, which is mainly composed of various collagen types. The activation of hepatic stellate cells (HSCs) to produce collagen is the main pathogenetic mechanism for the initiation of liver fibrosis and its progression to cirrhosis. The degree of liver fibrosis contributes significantly to the occurrence and severity of portal hypertension in patients with cirrhosis. These patients, particularly in more advanced stages, often present a tendency to hypercoagulability despite thrombocytopenia and prolonged clotting times, as in addition to the deficiency of procoagulant factors, there is usually a reduced production of anticoagulant factors, such as protein C (PC) and antithrombin. In addition, these patients often have high circulating levels of factor (F) VIII and von Willebrand factor antigen (vWf-Ag) due to their increased synthesis in the endothelium of the hepatic sinusoids. An increased FVIII/PC ratio in patients with cirrhosis indicates the presence of a procoagulant imbalance, while high levels of vWf enhance platelet adhesion and aggregation, even in the presence of thrombocytopenia. The prothrombotic state can lead to stimulation of thrombin production in the portal microcirculation, which directly activates HSCs through specific receptors, thereby increasing the secretion of extracellular matrix. In addition, the procoagulant activity predisposes to the development of intrasinusoidal microthrombi that initially lead to local ischemia and subsequently to parenchymal obliteration, thereby accelerating the progression of fibrosis. The role of inflammatory responses in hepatic fibrogenesis has also attracted increasing interest. In patients with cirrhosis, the liver is constantly exposed to bacterial products derived from the intestinal tract, including lipopolysaccharide (LPS), commonly referred to as endotoxin. This occurs due to bacterial translocation, which is caused by small intestinal bacterial overgrowth and increased intestinal permeability. Experimental findings indicate that LPS promotes the initiation and progression of liver fibrosis by activating HSCs via Toll-like receptors 4. In addition, LPS stimulates monocytes108and lymphocytes to produce proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), which have been reported to stimulate hepatic fibrogenesis. Liver biopsy is considered the method of choice for the assessment of liver fibrosis, but its invasive nature is a major drawback. Liver stiffness measurement (LSM) in kilopascals (kPa) by ultrasound elastography can effectively detect and stage liver fibrosis in patients with chronic liver diseases. In contrast to other elastographic methods, the application of two-dimensional shear wave elastography (2D-SWE) is not significantly limited by the presence of ascites. Objective: This prospective study investigated the relationship of procoagulant and systemic inflammatory activity with elastographically assessed liver fibrosis as well as the interaction between hemostatic balance and systemic inflammation in patients with cirrhosis. Methods: Patients with liver cirrhosis who were followed at the Hepatology outpatient clinic of the University Hospital of Ioannina from May 2020 to May 2025 were prospectively evaluated. The diagnosis of cirrhosis was based on a combination of clinical, laboratory, endoscopic and imaging findings or liver biopsy. Patients with thrombocytopenia, defined as a platelet count <150 x109/L and age between 18 and 75 years, were included. Exclusion criteria were: a) ascites requiring large-volume puncture, b) use of anticoagulant or antiplatelet drugs or other therapy known to affect blood coagulation and platelet function, c) known hemostatic disorders other than cirrhosis, d) use of pre-/probiotics or antibiotics in the last 6 weeks before enrollment, e) hepatic encephalopathy grade II or higher, variceal bleeding, and spontaneous bacterial peritonitis or other bacterial infection at least 3 months before study enrollment, f) serum creatinine levels >1.5 mg/dl, g) recent (within 6 months) or active ethanol abuse, h) history of portal vein thrombosis or other thrombotic episode, i) hepatocellular carcinoma or other malignancy, j) transjugular intrahepatic insertion portal vein bypass (k) history of cardiovascular, pulmonary or renal disease, and (l) uncontrolled diabetes. Primary prophylaxis for variceal bleeding included a beta-blocker, such as propranolol or carvedilol, endoscopic variceal ligation or a combination of the two. Demographic and clinical characteristics (age, gender, etiology of cirrhosis, previous decompensation, use of beta-blockers,109diabetes, and severity of cirrhosis based on Child-Pugh classification and MELD score) were recorded. 2D-SWE was performed to assess liver fibrosis by LSM. The patients were sequentially assigned to one of the following study groups until each group consisted of 100 patients: the first group included patients with LSM ≥25 kPa, which was defined as advanced liver fibrosis, while the second group included patients with LSM <25 kPa. Blood samples were taken to measure anti-hemostatic factors (platelet count, factors II, V, VII, IX, X, XI, XII, and XIII, fibrinogen, and α2-antiplasmin as an indicator of increased fibrinolysis), pro-hemostatic factors (FVIII, PC, protein S, antithrombin, vWf-Ag and markers of reduced fibrinolysis such as plasminogen and plasminogen activator inhibitor-1), and markers of systemic inflammatory activity such as serum levels of lipopolysaccharide-binding protein (LBP), TNF-α and IL-6. Plasma and serum samples were stored at -80°C until analysis. Routine laboratory tests, including INR as well as liver and kidney biochemistry, were also performed. Baseline characteristics were expressed as absolute and relative frequencies for categorical variables and as mean ± standard error for continuous variables. Pearson test and Student t-test were used to compare categorical and continuous variables, respectively. Variables that showed significance in univariate analysis were entered into a stepwise multivariate forward logistic regression analysis to identify independent prognostic factors associated with the presence of LSM ≥25kPa. Two multivariate models were used: one that included only coagulation parameters (model 1) and one that included coagulation parameters and inflammatory markers (model 2). Both multivariate models were adjusted for MELD score and the presence of decompensation. The relationship between LSM, coagulation parameters, and systemic inflammatory markers was assessed with the Spearman correlation coefficient. A p value < 0.05 was considered statistically significant. All statistical analyses were performed with the SPSS 26.0 statistical package (IBM Corp., Armonk, NY, USA).Results: No significant differences were observed between patient subgroups regarding age, gender, etiology of cirrhosis, beta-blocker use and the presence of diabetes. The presence of decompensation (p=0.004), particularly ascites (p=0.01), and the severity of liver disease, as assessed by MELD score110(p=0.01) and Child-Pugh classification (p=0.02), were significantly higher in patients with LSM≥25 kPa. As expected, LSM was significantly higher in patients with LSM≥25 kPa (range: 25-46 kPa) compared to those with LSM <25 kPa (range: 14-24.8 kPa) (p<0.001). The lower platelet count (p=0.009) and plasma levels of FII (p<0.001), FV (p=0.002), FII (p<0.001), FIX (p<0.001), FX (p=0.001), FXI (p=0.004), FXII (p=0.005) and FXIII (p=0.03), PC (p<0.001), antithrombin (p<0.001) and protein S (p=0.001), increased levels of FVIII (p<0.001) and vWf-Ag (p<0.001), and a higher FVIII/PC ratio (p<0.001) were significantly associated with the presence of LSM≥25 kPa in univariate analysis. Patients with LSM≥25 kPa had significantly higher serum levels of LBP (p<0.001), TNF-α (p<0.001) and IL-6 (p<0.001) compared to those with LSM<25kPa. In multivariate model 1, factor VIII (p=0.008), protein C (p=0.01), FVIII/PC ratio (p=0.002), and vWf-Ag (p=0.007) were independently associated with the presence of LSM≥25 kPa. FVIII/PC ratio (p=0.01) and vWf-Ag (p=0.04) remained the most significant predictors of the presence of LSM≥25 kPa after adjustment for MELD score and history of decompensation. In multivariate model 2, independent associations with the presence of LSM≥25 kPa were observed for FVIII (p=0.02), PC (p=0.05), FVIII/PC ratio (p=0.009), vWf-Ag (p=0.03), LBP (p=0.005), TNF-α (p=0.03), and IL-6 (p=0.04). When multivariate analysis was adjusted for MELD and decompensation at inclusion, FVIII/PC ratio (p=0.03) and LBP (p=0.01) were the only significant predictors of LSM ≥25 kPa. LSM was significantly correlated with the levels of FVIII (r=0.608; p<0.001), PC (r=-0.497; p<0.001), and vWf-Ag (r=0.621; p<0.001), and FVIII/PC ratio (r=0.640; p<0.001) in the total group of 200 patients. Additional significant correlations were found between LSM and serum levels of LBP (r=0.606; p<0.001), TNF-α (r=0.600; p<0.001), and IL-6 (r=0.557; p<0.001) among these patients. When analyzing LSM subgroups, the correlations of LSM with both coagulation parameters and systemic inflammation markers remained significant for patients with LSM≥25 kPa. Serum LBP, TNF-α and IL-6 concentrations showed significant correlations with the FVIII/PC ratio (r=0.523; p<0.001, r=0.493; p<0.001 and r=0.578; p<0.001, respectively) as well as with vWf-Ag levels (r=0.539; p<0.001, r=0.538; p<0.001 and r=0.439; p<0.001, respectively) in the entire cohort. The above correlations were also significant in both LSM subgroups.111 Conclusions: Advanced liver fibrosis, indicated by elastographic LSM ≥25 kPa, is closely associated with higher prothrombotic and systemic inflammatory activity, regardless of the severity of cirrhosis. A marked correlation of liver fibrosis with hemostatic parameters and markers of systemic inflammation was observed. The prothrombotic activity in patients with cirrhosis is closely related to systemic inflammation, regardless of the severity of hepatic fibrosis
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Angelis, Nikolaos
- Αγγέλης, Νικόλαος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61930